Duoc Cuu Long Pharmaceutical Joint Stock Company (DCL) has just released its consolidated financial report for Q3 and the first 9 months of 2023.
In the first three quarters, DCL recorded positive growth. By the end of Q3, DCL earned more than VND 262 billion in revenue, an increase of 4.55% compared to the same period; total assets increased from VND 2,105 billion to over VND 2,115 billion; owner’s equity increased from VND 1,391 billion to more than VND 1,421 billion. These results show a significant improvement in DCL’s business operations, maintaining growth momentum with the potential to make a breakthrough in the last three months of the year.
To achieve these results, DCL has focused on following the action strategy outlined in OGSM 2023, continuing to concentrate on manufacturing and trading key products such as empty capsules, cancer drugs, medical supplies, etc.
In the production and supply of various empty capsules, Duoc Cuu Long continues to maintain its market share in Vietnam and is currently expanding its Vicancap factory according to the set schedule. It is expected that by January 2024, when capsule line 5 goes into operation, the supply capacity will reach 9.6 billion capsules per year, equivalent to about 800 million capsules per month.
In the field of medical equipment, with the aim of improving production capacity to meet domestic demand and move towards international markets, DCL continues to ensure the construction progress of the Benovas Medical Equipment Manufacturing Factory. The project has an area of 11,000m2, with a total investment of VND 373 billion, divided into 2 phases and is expected to go into operation in Q2/2024.
In the field of pharmaceuticals, DCL is investing in a pharmaceutical factory meeting EU-GMP standards with a total investment of VND 1,035 billion. The production capacity of drugs and pharmaceuticals of the factory reaches 1.6 billion products per year. Once the project is completed and operational, it will mark a significant step forward for Duoc Cuu Long in particular, contributing to the development of the Vietnamese pharmaceutical industry in general.
Recognizing DCL’s contributions to producing quality products, in August, the Consumer Protection Center and the Institute of Economics & Culture awarded the gold cup and certificate for the Cefixim 200 brand, which ranked in the Top 10 quality products of 2023. This is not the first time that DCL’s Cefixim 200 has been voted as a quality product for consumer rights for many years. The Cefixim 200 brand is one of the products that makes DCL proud. The product is manufactured under strict control procedures, advanced technology, and has become a reputable brand trusted by large hospitals and patients across the country.
Cefixim Certified as Top 10 High-Quality Product – For Consumer Rights 2023
At the end of Q3/2023, DCL continues to adhere to its business plan for 2023 with a target of reaching VND 1,150 billion in net revenue, an increase of 13.2% compared to 2022; pre-tax profit reaching over VND 160 billion, an increase of 13.1% compared to 2022.
With its steady growth momentum, DCL is gradually moving towards its vision of becoming the most highly regarded pharmaceutical company in Vietnam by patients, partners, and employees through innovative, accessible products and the best care.
